IL208387A0 - Pharmaceutical composition - Google Patents

Pharmaceutical composition

Info

Publication number
IL208387A0
IL208387A0 IL208387A IL20838710A IL208387A0 IL 208387 A0 IL208387 A0 IL 208387A0 IL 208387 A IL208387 A IL 208387A IL 20838710 A IL20838710 A IL 20838710A IL 208387 A0 IL208387 A0 IL 208387A0
Authority
IL
Israel
Prior art keywords
pharmaceutical composition
pharmaceutical
composition
Prior art date
Application number
IL208387A
Original Assignee
Robert Shorr
Robert Rodriguez
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Robert Shorr, Robert Rodriguez filed Critical Robert Shorr
Publication of IL208387A0 publication Critical patent/IL208387A0/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/38Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL208387A 2008-04-04 2010-10-03 Pharmaceutical composition IL208387A0 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2008/004410 WO2009123597A1 (en) 2008-04-04 2008-04-04 Pharmaceutical composition

Publications (1)

Publication Number Publication Date
IL208387A0 true IL208387A0 (en) 2010-12-30

Family

ID=41135840

Family Applications (1)

Application Number Title Priority Date Filing Date
IL208387A IL208387A0 (en) 2008-04-04 2010-10-03 Pharmaceutical composition

Country Status (10)

Country Link
EP (1) EP2268278A4 (en)
JP (1) JP2011516473A (en)
KR (1) KR20110025168A (en)
CN (1) CN102056605A (en)
AU (1) AU2008354009A1 (en)
BR (1) BRPI0821894A2 (en)
CA (1) CA2720396A1 (en)
IL (1) IL208387A0 (en)
MX (1) MX2010010867A (en)
WO (1) WO2009123597A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX343847B (en) 2010-07-08 2016-11-24 Wrigley W M Jun Co Chewing gum containing a cross-linked gelatin matrix gum base.
US9421234B2 (en) * 2011-05-20 2016-08-23 Nutramax Laboratories, Inc. Orally administrable compositions comprising avocado/soybean unsaponifiables and lipoic acid and methods of administration
US9708411B2 (en) * 2012-02-16 2017-07-18 The Penn Research Foundation Modulators of acyl-CoA lysocardiolipin acyltransferase 1 (ALCAT1) and uses thereof
JP6395724B2 (en) * 2012-12-19 2018-09-26 ロバート・ショア Pharmaceutical compounds
WO2015195070A1 (en) 2014-06-19 2015-12-23 Robert Shorr Pharmaceutical compounds
AU2014398233B2 (en) 2014-06-19 2019-11-28 Rafael Pharmaceuticals, Inc. Pharmaceutical compounds
CN110590624B (en) * 2019-09-26 2021-02-26 苏州富士莱医药股份有限公司 Preparation method of lipoic acid derivative 8- (ethyl disulfide) -6- (phenyl disulfide) caprylic acid
WO2023012305A1 (en) * 2021-08-04 2023-02-09 Cytacoat Ab Disulfide compounds as medicaments
CN118236491A (en) * 2022-12-23 2024-06-25 中国科学院上海营养与健康研究所 PDK4 as cell senescence intervention target and application thereof in chemotherapy and anticancer

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2853497A (en) * 1953-12-04 1958-09-23 Merck & Co Inc 6, 8-bis (hydrocarbon substituted mercapto) 5-hydroxycaprylic acids and delta-lactones thereof
US2789991A (en) * 1954-05-20 1957-04-23 American Cyanamid Co Substituted disulfones
JPS61198148A (en) * 1985-01-29 1986-09-02 Fuji Photo Film Co Ltd Silver halide photographic sensitive material
GB9618934D0 (en) * 1996-09-11 1996-10-23 Univ London Inositol phosphoglycans for therapeutic use in the treatment of diabetes and obesity
KR101054060B1 (en) * 1998-03-20 2011-08-04 커먼웰쓰 사이언티픽 앤드 인더스트리얼 리서치 오가니제이션 Control of gene expression
FR2777001B1 (en) * 1998-04-01 2000-06-09 Cird Galderma 6,8-DIMERCAPTOOCTANOIC ACID DERIVATIVES SUBSTITUTED IN 6-S AND / OR 8-S BY RADICAL (3-METHYLTHIOPROPANOYL) AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CANCER TUMORS
US6331559B1 (en) * 1998-10-26 2001-12-18 The Research Foundation Of State University Of New York At Stony Brook Lipoic acid derivatives and their use in treatment of disease
DE19904794A1 (en) * 1999-02-05 2000-08-10 Biotechnolog Forschung Gmbh Methods for improving the primary metabolism of mammalian cell lines
US6284786B1 (en) * 1999-02-16 2001-09-04 The Center For The Improvement Of Human Functioning, Int'l., Inc. Treatment of cancer using lipoic acid in combination with ascorbic acid
AR042572A1 (en) * 1999-04-02 2005-06-29 Sod Conseils Rech Applic DERIVATIVES OF LIPOIC ACID, PROCEDURE FOR THE PREPARATION, MEDICINES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND USE OF SUCH DERIVATIVES FOR THE PREPARATION OF THE REFERRED MEDICATIONS
IT1312060B1 (en) * 1999-04-09 2002-04-04 Antibioticos Spa USE OF ALPHA LIPOIC ACID IN ANTIMETASTATIC TREATMENT.
JP2004500852A (en) * 2000-05-19 2004-01-15 エフ. ホフマン−ラ ロシュ アーゲー Process for determining the tumoricidal potential of a sample by using nucleic acids that are down-regulated in human tumor cells
WO2006119355A2 (en) * 2005-05-03 2006-11-09 Albert Einstein College Of Medicine Of Yeshiva University Mammalian hypothalamic nutrient modulation of glucose metabolism
US20070077583A1 (en) * 2005-09-21 2007-04-05 Aurelium Biopharma, Inc. Alpha enolase-directed diagnostics and therapeutics for cancer and chemotherapeutic drug resistance
US20070212360A1 (en) * 2006-01-17 2007-09-13 Denko Nicholas C Modulation of mitochondrial oxygen consumption for therapeutic purposes
NZ580973A (en) * 2007-04-18 2011-10-28 Cornerstone Pharmaceuticals Inc Pharmaceutical formulations containing lipoic acid derivatives
EP2139321B1 (en) * 2007-04-18 2013-11-06 Cornerstone Pharmaceuticals, Inc. Lipoic acid derivatives
CA2717511A1 (en) * 2008-03-04 2009-09-11 Robert Shorr Modulation of enzymatic structure, activity, and/or expression level

Also Published As

Publication number Publication date
CA2720396A1 (en) 2009-10-08
AU2008354009A1 (en) 2009-10-08
KR20110025168A (en) 2011-03-09
CN102056605A (en) 2011-05-11
JP2011516473A (en) 2011-05-26
BRPI0821894A2 (en) 2015-07-21
WO2009123597A1 (en) 2009-10-08
MX2010010867A (en) 2011-05-25
EP2268278A1 (en) 2011-01-05
EP2268278A4 (en) 2011-11-09

Similar Documents

Publication Publication Date Title
HUS1800007I1 (en) Pharmaceutical composition
IL228817A0 (en) Pharmaceutical composition
EP2240022A4 (en) Pharmaceutical compositions
GB0814695D0 (en) Pharmaceutical compositions
EP2133095A4 (en) Pharmaceutical composition
EP2133094A4 (en) Pharmaceutical composition
EP2373681A4 (en) Pharmaceutical compositions
EP2191826A4 (en) Pharmaceutical composition
PT2323623T (en) Pharmaceutical compositions
IL200125A0 (en) Pharmaceutical composition
EP2236149A4 (en) Medicinal composition
EP2224805A4 (en) Pharmaceutical composition
EP2224915A4 (en) Pharmaceutical composition
ZA201102715B (en) Solid pharmaceutical composition
IL208387A0 (en) Pharmaceutical composition
HK1138774A1 (en) Pharmaceutical composition
EP2224808A4 (en) Pharmaceutical composition
ZA201100871B (en) Solid pharmaceutical composition
EP2156832A4 (en) Pharmaceutical composition
ZA201006224B (en) Pharmaceutical composition
EP2327406A4 (en) Stabilized pharmaceutical composition
GB2464200B (en) Pharmaceutical composition
IL206487A0 (en) Pharmaceutical compositions
EP2224806A4 (en) Pharmaceutical composition
GB0817969D0 (en) Pharmaceutical composition